Dragonfly to receive a $12 million payment and is eligible to receive potential future milestones and royalties on net sales. WALTHAM, Massachusetts, Aug. 10, 2020 /PRNewswire/ -- Dragonfly ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Bristol Myers Squibb will pay $475 million to license an experimental cytokine drug from Dragonfly Therapeutics. The therapy, called DF6002, is an IL-12 immunoglobulin Fc fusion protein. IL-12 helps ...
Bristol Myers Squibb (BMS) has inked a deal with Dragonfly Therapeutic for an exclusive license to its interleukin-12 immunotherapy programme. BMS will pay Dragonfly $245m upfront, with the further ...
Dragonfly Therapeutics Inc, announced that Bristol Myers Squibb has licensed its fourth TriNKET immunotherapy drug candidate from Dragonfly, a clinical-stage biopharmaceutical company. Since the ...
Dr. Eid joins Dragonfly after 20 years of clinical development experience at Roche, Merck and BMS including as team leader at Merck in the Pembrolizumab (anti-PD-1 antibody) first in human trial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results